Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:60080 |
Name | Her2-receptor negative breast cancer |
Definition | A breast cancer that is characterized by the absence of Her2 receptors. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer Her2-receptor negative breast cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PIK3CA mutant | Capivasertib + Paclitaxel | Her2-receptor negative breast cancer | no benefit | detail... |
FGFR1 amp | Pazopanib | Her2-receptor negative breast cancer | predicted - sensitive | detail... |
RB1 K240Sfs*22 TP53 R248W | Fulvestrant + Palbociclib | Her2-receptor negative breast cancer | predicted - resistant | detail... |
RB1 I101fs RB1 E268* RB1 V654fs RB1 T738_R775del | Fulvestrant + Palbociclib | Her2-receptor negative breast cancer | predicted - resistant | detail... |
RB1 H483Y | Letrozole + Ribociclib | Her2-receptor negative breast cancer | predicted - resistant | detail... |
PIK3CA mutant | Alpelisib | Her2-receptor negative breast cancer | sensitive | detail... |
PIK3CA wild-type | Alpelisib | Her2-receptor negative breast cancer | no benefit | detail... |
FBXW7 mutant | LY3039478 | Her2-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA mutant | Everolimus | Her2-receptor negative breast cancer | no benefit | detail... |
PIK3CA exon10 | Everolimus | Her2-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA exon21 | Everolimus | Her2-receptor negative breast cancer | no benefit | detail... |
PIK3CA H1047R | Everolimus | Her2-receptor negative breast cancer | no benefit | detail... |
PIK3CA E545K | Everolimus | Her2-receptor negative breast cancer | no benefit | detail... |
PIK3CA E542K | Everolimus | Her2-receptor negative breast cancer | no benefit | detail... |
FGFR1 amp | Lucitanib | Her2-receptor negative breast cancer | predicted - sensitive | detail... |
FGFR1 over exp | Lucitanib | Her2-receptor negative breast cancer | predicted - sensitive | detail... |
PTEN R130* | Alpelisib + Letrozole | Her2-receptor negative breast cancer | predicted - resistant | detail... |
ATM T2333fs ATM neg | Elimusertib | Her2-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA act mut | Alpelisib + Nab-paclitaxel | Her2-receptor negative breast cancer | predicted - sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | Her2-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA H1047R | STX-478 | Her2-receptor negative breast cancer | sensitive | detail... |
PIK3CA H1047L | HS-10352 | Her2-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA H1047R | HS-10352 | Her2-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA E542K | HS-10352 | Her2-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA E545D | HS-10352 | Her2-receptor negative breast cancer | predicted - sensitive | detail... |
PIK3CA E545K | HS-10352 | Her2-receptor negative breast cancer | predicted - sensitive | detail... |
FGFR2 T319I PIK3CA N345K PIK3CA E453K | Inavolisib | Her2-receptor negative breast cancer | predicted - resistant | detail... |
FGFR2 rearrange | Tinengotinib | Her2-receptor negative breast cancer | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00764972 | Phase Ib/II | Sorafenib + Vinorelbine | Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer | Unknown status | CAN | 0 |
NCT00921115 | Phase II | Anastrozole Fulvestrant | Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. | Completed | USA | 0 |
NCT00971737 | Phase II | Trastuzumab Cyclophosphamide | Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer | Completed | USA | 0 |
NCT01036087 | Phase II | Carboplatin + Nab-paclitaxel + Panitumumab Cyclophosphamide + Epirubicin + Fluorouracil | Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer | Completed | USA | 0 |
NCT01116648 | Phase Ib/II | Olaparib Cediranib + Olaparib | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT01145430 | Phase I | Pegylated liposomal doxorubicin + Veliparib | Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer | Completed | USA | 0 |
NCT01262027 | Phase II | Dovitinib | TKI258 for Metastatic Inflammatory Breast Cancer Patients | Completed | USA | 0 |
NCT01272037 | Phase III | Anastrozole Letrozole Tamoxifen Exemestane | Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer | Active, not recruiting | USA | IRL | FRA | ESP | CAN | 5 |
NCT01292655 | Phase I | BMS-906024 | Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | Completed | USA | CAN | AUS | 0 |
NCT01351909 | Phase I | Cyclophosphamide Veliparib | Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT01437566 | Phase II | Apitolisib Fulvestrant Pictilisib | Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy | Completed | USA | NZL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | ARG | 10 |
NCT01441947 | Phase II | Cabozantinib + Fulvestrant | Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT01467310 | Phase I | Trametinib | Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 | Completed | USA | 0 |
NCT01479244 | Phase III | E75 Sargramostim | Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence | Completed | USA | ROU | POL | ISR | HUN | GBR | FRA | DEU | CAN | BGR | 3 |
NCT01484041 | Phase Ib/II | Dovitinib | Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer | Terminated | USA | 0 |
NCT01528345 | Phase II | Dovitinib + Fulvestrant Fulvestrant | Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer | Terminated | USA | POL | NLD | ITA | HUN | FRA | ESP | BRA | BEL | AUT | ARG | 4 |
NCT01560416 | Phase II | Fulvestrant Ganetespib | Fulvestrant With or Without Ganetespib in HR+ Breast Cancer | Active, not recruiting | USA | 0 |
NCT01572727 | Phase II | Buparlisib + Paclitaxel Paclitaxel | A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation | Completed | USA | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | AUS | 8 |
NCT01610284 | Phase III | Buparlisib + Fulvestrant Fulvestrant | Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2)r | Completed | USA | SVK | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT01633060 | Phase III | Fulvestrant Buparlisib + Fulvestrant | A Phase III Study of BKM120 With Fulvestrant in Patients With HR+, HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi | Terminated | USA | SWE | POL | NOR | NLD | LBN | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CAN | BGR | BEL | AUT | ARG | 3 |
NCT01670877 | Phase II | Neratinib Neratinib + Trastuzumab Fulvestrant + Neratinib + Trastuzumab Fulvestrant + Neratinib | Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer | Completed | USA | CAN | 0 |
NCT01674140 | Phase III | Goserelin Anastrozole Letrozole Leuprolide Everolimus Tamoxifen Exemestane | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3) | Active, not recruiting | USA | 1 |
NCT01698918 | Phase II | Everolimus + Exemestane Everolimus + Letrozole | Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer | Completed | USA | TUR | NLD | HUN | GBR | FRA | ESP | BRA | ARG | 4 |
NCT01757327 | Phase II | Sonidegib | LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer | Withdrawn | 0 | |
NCT01776008 | Phase II | Goserelin + MK2206 | Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer | Terminated | USA | 0 |
NCT01779050 | Phase II | Trastuzumab Docetaxel Cyclophosphamide + Epirubicin Paclitaxel Cyclophosphamide + Epirubicin + Fluorouracil Carboplatin + Docetaxel Cyclophosphamide + Docetaxel | Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells | Terminated | USA | 0 |
NCT01791478 | Phase I | Alpelisib + Letrozole | BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT01792050 | Phase II | Docetaxel Indoximod Paclitaxel | Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer | Completed | USA | POL | 0 |
NCT01797120 | Phase II | Everolimus + Fulvestrant Fulvestrant | Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI | Completed | USA | 0 |
NCT01803282 | Phase I | Andecaliximab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Carboplatin + Pemetrexed Disodium Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Carboplatin + Paclitaxel Paclitaxel Bevacizumab | Safety and Tolerability Study in Solid Tumors | Completed | USA | 0 |
NCT01823835 | Phase II | GDC-0810 | A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer | Terminated | USA | NLD | ESP | 1 |
NCT01837602 | Phase I | cMet CAR RNA T Cells Targeting Breast Cancer | Completed | USA | 0 | |
NCT01894451 | Phase I | Bevacizumab | Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy | Completed | USA | 0 |
NCT01905592 | Phase III | Niraparib | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (BRAVO) | Terminated | USA | POL | NLD | ITA | ISR | ISL | HUN | GRC | GBR | FRA | ESP | CAN | BEL | 1 |
NCT01918306 | Phase Ib/II | Cisplatin Cisplatin + Pictilisib | GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer | Terminated | USA | 0 |
NCT01923168 | Phase II | Buparlisib + Letrozole Letrozole Alpelisib + Letrozole | Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women | Completed | USA | NLD | LBN | ITA | ISR | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | 3 |
NCT01953588 | Phase III | Anastrozole Fulvestrant | Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | Active, not recruiting | USA | 1 |
NCT01958021 | Phase III | Letrozole + Ribociclib Letrozole | Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) | Completed | USA | TUR | SWE | NOR | NLD | LBN | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT01963481 | Phase II | Cyclophosphamide Exemestane | Exemestane and Cyclophosphamide for Metastatic Breast Cancer | Completed | USA | 0 |
NCT01964924 | Phase II | Trametinib + Uprosertib | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer | Completed | USA | 0 |
NCT01969643 | Phase I | Ladiratuzumab vedotin Ladiratuzumab vedotin + Trastuzumab | A Safety Study of SGN-LIV1A in Breast Cancer Patients | Completed | USA | 0 |
NCT02010021 | Phase I | Letrozole | Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer. | Completed | USA | 0 |
NCT02032277 | Phase III | Cyclophosphamide + Doxorubicin Veliparib Carboplatin Carboplatin + Paclitaxel | A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer | Completed | USA | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUS | 3 |
NCT02032823 | Phase III | Olaparib | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA) | Active, not recruiting | USA | SWE | POL | NLD | ITA | ISR | ISL | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUT | AUS | ARG | 6 |
NCT02038699 | Phase Ib/II | ONC201 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Withdrawn | USA | 0 |
NCT02040857 | Phase II | Exemestane Palbociclib Tamoxifen Letrozole Anastrozole | A Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer | Completed | USA | 0 |
NCT02049957 | Phase Ib/II | Fulvestrant + Sapanisertib Exemestane + Sapanisertib | Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer | Completed | USA | FRA | BEL | 0 |
NCT02057133 | Phase I | Abemaciclib + Loperamide + Pertuzumab + Trastuzumab Abemaciclib + Fulvestrant + LY3023414 Abemaciclib + Letrozole Abemaciclib + Exemestane Abemaciclib Abemaciclib + Everolimus + Exemestane Abemaciclib + Anastrozole Abemaciclib + Tamoxifen Abemaciclib + Trastuzumab | A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | Active, not recruiting | USA | 0 |
NCT02074878 | Phase I | Crizotinib + Sunitinib | CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer | Terminated | USA | 0 |
NCT02088684 | Phase Ib/II | Buparlisib + Fulvestrant + Ribociclib Fulvestrant + Ribociclib Alpelisib + Fulvestrant + Ribociclib | Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer | Completed | USA | ITA | GBR | FRA | ESP | 3 |
NCT02095184 | Phase 0 | Anastrozole Letrozole | GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients | Recruiting | USA | 0 |
NCT02107703 | Phase III | Abemaciclib + Fulvestrant Fulvestrant | A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer (MONARCH 2) | Active, not recruiting | USA | ROU | POL | ITA | GRC | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BEL | AUS | 6 |
NCT02115048 | Phase II | Afatinib Letrozole | Clinical Study for the Treatment of Breast Cancer the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone | Terminated | USA | ROU | ESP | 1 |
NCT02120417 | Phase II | Capecitabine + Ruxolitinib Capecitabine | A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer | Terminated | USA | ITA | GBR | FRA | ESP | 1 |
NCT02137837 | Phase III | Everolimus + Fulvestrant Anastrozole + Everolimus + Fulvestrant Fulvestrant | S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer | Terminated | USA | 0 |
NCT02142868 | Phase III | Letrozole + Palbociclib | Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate | No longer available | USA | CAN | 0 |
NCT02154776 | Phase I | Buparlisib + Letrozole + Ribociclib | Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (LeeBLet) | Completed | USA | ESP | 0 |
NCT02157051 | Phase I | Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer | Active, not recruiting | USA | 0 | |
NCT02163694 | Phase III | Carboplatin + Paclitaxel + Veliparib Carboplatin + Paclitaxel | A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer | Completed | USA | TUR | SWE | ROU | POL | NOR | NLD | LVA | LTU | ITA | ISR | HUN | GBR | FRA | FIN | EST | ESP | DNK | DEU | CZE | CAN | BEL | AUT | AUS | ARG | 12 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02187991 | Phase II | Paclitaxel Alisertib + Paclitaxel | Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer | Completed | USA | 0 |
NCT02188745 | Phase II | Exemestane Estradiol Anastrozole Letrozole | ER Reactivation Therapy for Breast Cancer (POLLY) | Completed | USA | 0 |
NCT02204098 | Phase I | Mammaglobin-A | Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy | Active, not recruiting | USA | 0 |
NCT02236572 | Phase II | Everolimus | Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score | Terminated | USA | 0 |
NCT02246621 | Phase III | Abemaciclib + Anastrozole + Letrozole Anastrozole + Letrozole | A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3) | Active, not recruiting | USA | TUR | SWE | SVK | NZL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 5 |
NCT02248090 | Phase I | AZD9496 | AZD9496 First Time in Patients Ascending Dose Study | Completed | USA | GBR | 1 |
NCT02258451 | Phase II | Everolimus + Exemestane Radium Ra 223 dichloride | Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer | Completed | USA | POL | NOR | ITA | ISR | GBR | FRA | ESP | DEU | CHE | BEL | AUT | 5 |
NCT02258464 | Phase II | Radium Ra 223 dichloride | Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer | Terminated | USA | POL | NOR | NLD | ISR | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | AUT | 4 |
NCT02259114 | Phase I | Birabresib | A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors | Completed | 0 | |
NCT02260661 | Phase I | Fulvestrant AZD8835 | Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours | Completed | USA | GBR | 0 |
NCT02264678 | Phase Ib/II | Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib | Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents | Recruiting | USA | HUN | GBR | FRA | ESP | CAN | BEL | AUS | 1 |
NCT02269670 | Phase II | Tamoxifen Everolimus Megestrol acetate Letrozole Fulvestrant Anastrozole | Phase II Study of Everolimus Beyond Progression | Terminated | USA | 0 |
NCT02273752 | Phase II | Everolimus | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | Terminated | USA | 0 |
NCT02273973 | Phase II | Taselisib | Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI) | Completed | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CHE | BRA | BEL | AUT | AUS | 8 |
NCT02278120 | Phase III | Goserelin + Ribociclib + Tamoxifen Goserelin + Tamoxifen Anastrozole + Goserelin Goserelin + Letrozole Goserelin + Letrozole + Ribociclib Anastrozole + Goserelin + Ribociclib | Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (MONALEESA-7) | Completed | USA | TUR | POL | LBN | ITA | HUN | GRC | FRA | ESP | DEU | CHE | CAN | BRA | BGR | BEL | AUS | ARG | 13 |
NCT02282345 | Phase II | Talazoparib | Talazoparib Before Standard Therapy in Treating Patients With Invasive, BRCA-Mutated Breast Cancer | Completed | USA | 0 |
NCT02286843 | Phase I | Trastuzumab | Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy? | Completed | USA | 0 |
NCT02291913 | Phase II | Everolimus + Tamoxifen Anastrozole + Everolimus Everolimus + Fulvestrant Everolimus + Letrozole Everolimus + Toremifene Everolimus + Exemestane | Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer | Completed | USA | 0 |
NCT02296801 | Phase II | Palbociclib Letrozole | A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer | Completed | USA | GBR | CAN | 0 |
NCT02301988 | Phase II | Paclitaxel Ipatasertib | A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer | Completed | USA | ESP | 1 |
NCT02308020 | Phase II | Abemaciclib | A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain | Completed | USA | ITA | ISR | FRA | ESP | CAN | BEL | AUT | AUS | 0 |
NCT02309177 | Phase I | Carboplatin Gemcitabine Nab-paclitaxel + Nivolumab | Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer | Completed | USA | 0 |
NCT02311933 | Phase II | Z-endoxifen HCl Tamoxifen | Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02323191 | Phase I | Atezolizumab + Emactuzumab | A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | FRA | ESP | BEL | 0 |
NCT02352025 | Phase I | S-equol | S-equol in Women With Triple Negative Breast Cancer | Completed | USA | 0 |
NCT02374099 | Phase II | Azacitidine Fulvestrant | Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant | Terminated | USA | ITA | FRA | ESP | DEU | BEL | 0 |
NCT02379247 | Phase Ib/II | Alpelisib + Nab-paclitaxel | BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer | Completed | USA | 0 |
NCT02384239 | Phase II | Fulvestrant + Palbociclib Palbociclib + Tamoxifen | A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer | Completed | USA | 0 |
NCT02384746 | Phase I | Fulvestrant + Ixazomib | Phase I Study of the Combination of MLN9708 and Fulvestrant | Terminated | USA | 0 |
NCT02387099 | Phase II | Everolimus | Dose EScalation Induction of EvERolimus (Desiree) | Completed | DEU | 0 |
NCT02389764 | Phase II | Nintedanib | Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC) | Terminated | USA | 0 |
NCT02401347 | Phase II | Talazoparib | Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors | Completed | USA | 0 |
NCT02402764 | Phase II | Selinexor | Phase 2 Trial of Selinexor (KPT-330) for Metastatic TNBC | Completed | USA | 0 |
NCT02403271 | Phase Ib/II | Durvalumab + Ibrutinib | A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors | Completed | USA | 0 |
NCT02422615 | Phase III | Fulvestrant Fulvestrant + Ribociclib | Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. (MONALEESA-3) | Completed | USA | TUR | SWE | POL | NOR | NLD | LBN | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BGR | BEL | AUT | AUS | 9 |
NCT02437318 | Phase III | Alpelisib Fulvestrant | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1) | Completed | USA | SWE | ROU | NLD | LBN | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 10 |
NCT02441946 | Phase II | Abemaciclib Loperamide Anastrozole | A Phase 2 Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer | Completed | USA | NLD | ITA | ESP | DEU | CAN | BEL | AUT | 2 |
NCT02448771 | Phase Ib/II | Bazedoxifene + Palbociclib | A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer | Completed | USA | 0 |
NCT02453620 | Phase I | Entinostat + Ipilimumab + Nivolumab | Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02457910 | Phase Ib/II | Enzalutamide Enzalutamide + Taselisib | Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer | Terminated | USA | 0 |
NCT02463032 | Phase II | Enobosarm | Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer | Completed | USA | 0 |
NCT02476786 | Phase II | Anastrozole Fulvestrant Goserelin Tamoxifen Exemestane | Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | Recruiting | USA | 0 |
NCT02481050 | Phase II | Eribulin | Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer | Completed | USA | 0 |
NCT02513394 | Phase III | Palbociclib | PALbociclib CoLlaborative Adjuvant Study (PALLAS) | Active, not recruiting | USA | SWE | POL | NLD | ITA | ISR | IRL | HUN | GBR | ESP | DEU | CHE | CAN | BEL | AUT | AUS | 5 |
NCT02520063 | Phase Ib/II | Carotuximab + Everolimus + Letrozole | Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer | Completed | USA | 0 |
NCT02536794 | Phase II | Durvalumab + Tremelimumab | MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer | Completed | USA | 0 |
NCT02561832 | Phase I | Cyclophosphamide Olaparib Carboplatin | A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer | Terminated | USA | ESP | 0 |
NCT02575781 | Phase I | SAR428926 | A Study of SAR428926 in Patients With Advanced Solid Tumors | Completed | FRA | ESP | DNK | 0 |
NCT02586675 | Phase I | Goserelin Ribociclib + Tamoxifen | TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer | Completed | USA | 0 |
NCT02619669 | Phase I | Sapanisertib Letrozole | Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer | Withdrawn | USA | 0 |
NCT02626507 | Phase I | Palbociclib Gedatolisib Goserelin Fulvestrant | Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer | Unknown status | USA | 0 |
NCT02630368 | Phase Ib/II | Avelumab + Cyclophosphamide + JX-594 Cyclophosphamide + JX-594 Cyclophosphamide | A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX) (METROmaJX) | Unknown status | FRA | 0 |
NCT02630693 | Phase II | Palbociclib Fulvestrant Tamoxifen | Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer | Completed | CAN | 0 |
NCT02632045 | Phase II | Fulvestrant + Ribociclib Fulvestrant | Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer (MAINTAIN) | Active, not recruiting | USA | 0 |
NCT02648477 | Phase II | Letrozole + Pembrolizumab Exemestane + Pembrolizumab Anastrozole + Pembrolizumab Doxorubicin + Pembrolizumab | Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer | Completed | USA | 0 |
NCT02651610 | Phase II | Bavituximab Paclitaxel | Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer | Withdrawn | USA | 0 |
NCT02668666 | Phase II | Palbociclib + Tamoxifen | Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer | Completed | USA | 0 |
NCT02684032 | Phase I | Letrozole Fulvestrant Gedatolisib + Palbociclib | A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer | Completed | USA | 0 |
NCT02692755 | Phase II | Fulvestrant + Palbociclib Letrozole + Palbociclib | Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer (PALINA) | Completed | USA | 0 |
NCT02712723 | Phase II | Letrozole + Ribociclib | Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer (FELINE) | Unknown status | USA | 0 |
NCT02732119 | Phase Ib/II | Everolimus + Exemestane + Ribociclib | Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (TRINITI-1) | Completed | USA | 0 |
NCT02738866 | Phase II | Fulvestrant + Palbociclib | Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor | Active, not recruiting | USA | 0 |
NCT02747004 | Phase II | Abemaciclib + Loperamide Abemaciclib Abemaciclib + Tamoxifen | A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (Next MONARCH 1) | Active, not recruiting | USA | TUR | ITA | FRA | ESP | DEU | CZE | BRA | BEL | AUT | ARG | 3 |
NCT02752685 | Phase II | Nab-paclitaxel + Pembrolizumab | Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT02753686 | Phase I | Tamoxifen Exemestane Fulvestrant Letrozole Anastrozole Everolimus + Exemestane | Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight) | Completed | CAN | 0 |
NCT02756364 | Phase II | Fulvestrant + Sapanisertib Fulvestrant | MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy | Completed | USA | ESP | 0 |
NCT02760030 | Phase II | Fulvestrant + Palbociclib | Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery | Recruiting | USA | 0 |
NCT02761694 | Phase I | ARQ 751 + Paclitaxel ARQ 751 ARQ 751 + Fulvestrant | ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations | Terminated | USA | 0 |
NCT02764541 | Phase II | Palbociclib Palbociclib + Tamoxifen Letrozole Tamoxifen | Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS) | Active, not recruiting | USA | 0 |
NCT02776917 | Phase I | Cirmtuzumab + Paclitaxel | Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer | Completed | USA | 0 |
NCT02778685 | Phase II | Fulvestrant + Palbociclib + Pembrolizumab Letrozole + Palbociclib + Pembrolizumab | Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients with Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT02779751 | Phase II | Abemaciclib + Pembrolizumab | A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer | Active, not recruiting | USA | TUR | ITA | FRA | ESP | BEL | 1 |
NCT02792114 | Phase I | Rimiducid Mesothelin CAR-T cells Cyclophosphamide | T-Cell Therapy for Advanced Breast Cancer | Active, not recruiting | USA | 0 |
NCT02792725 | Expanded access | Abemaciclib | Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer | Approved for marketing | USA | 0 |
NCT02811497 | Phase II | Azacitidine + Durvalumab | Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR) | Completed | CAN | 0 |
NCT02824575 | Phase I | Paclitaxel + Rebastinib Eribulin + Rebastinib | Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer | Terminated | USA | 0 |
NCT02849496 | Phase II | Olaparib Atezolizumab + Olaparib | Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer | Active, not recruiting | USA | 0 |
NCT02860000 | Phase II | Alisertib + Fulvestrant Alisertib | Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer | Active, not recruiting | USA | 0 |
NCT02871791 | Phase Ib/II | Everolimus + Exemestane + Palbociclib | Palbociclib With Everolimus + Exemestane In BC | Completed | USA | 0 |
NCT02892734 | Phase II | Ipilimumab + Nivolumab | Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer | Terminated | USA | 0 |
NCT02936206 | Phase I | Tamoxifen Fulvestrant | Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. | Terminated | USA | 0 |
NCT02941926 | Phase III | Letrozole + Ribociclib Leuprolide Goserelin | Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC | Completed | USA | SWE | SVN | SVK | POL | NOR | NLD | LBN | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | CZE | CAN | BGR | BEL | AUT | ARG | 15 |
NCT02942355 | Phase II | Anastrozole + Palbociclib | Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT02953860 | Phase II | Enzalutamide + Fulvestrant | Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer | Completed | USA | 0 |
NCT02955394 | Phase II | Fulvestrant Enzalutamide + Fulvestrant | Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer | Active, not recruiting | USA | 0 |
NCT02957968 | Phase II | Decitabine + Pembrolizumab Cyclophosphamide + Doxorubicin Carboplatin + Paclitaxel Paclitaxel | Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca | Active, not recruiting | USA | 0 |
NCT02983604 | Phase Ib/II | Exemestane Fulvestrant + GS-5829 Exemestane + GS-5829 Fulvestrant | GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | Terminated | USA | 0 |
NCT03007979 | Phase II | Goserelin Fulvestrant + Palbociclib Letrozole + Palbociclib | Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer | Completed | USA | 0 |
NCT03018080 | Phase II | Paclitaxel + Pembrolizumab | Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy) | Completed | USA | 0 |
NCT03044730 | Phase II | Capecitabine + Pembrolizumab | Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery | Unknown status | USA | 0 |
NCT03050398 | Phase III | Letrozole + Ribociclib | A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib | Terminated | USA | 0 |
NCT03051659 | Phase II | Eribulin Eribulin + Pembrolizumab | A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer | Completed | USA | 0 |
NCT03051672 | Phase II | Pembrolizumab | Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC | Terminated | USA | 0 |
NCT03056755 | Phase II | Alpelisib + Fulvestrant Alpelisib + Letrozole | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments (BYLieve) | Active, not recruiting | USA | NLD | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BEL | ARG | 7 |
NCT03070002 | Phase II | Denosumab | Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells | Terminated | USA | 0 |
NCT03078751 | Phase II | Ribociclib | Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1) | Completed | USA | 0 |
NCT03088527 | Phase I | RAD140 | Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer | Completed | USA | 0 |
NCT03092934 | Phase Ib/II | LY3295668 | A Study of AK-01 (LY3295668) in Solid Tumors | Completed | CAN | 0 |
NCT03128619 | Phase Ib/II | Copanlisib + Letrozole + Palbociclib Copanlisib + Letrozole | Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer | Terminated | USA | 0 |
NCT03132467 | Phase I | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer | Completed | USA | 0 |
NCT03134638 | Phase I | Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365 | A Study of SY-1365 in Adult Patients With Advanced Solid Tumors | Terminated | USA | FRA | CAN | 0 |
NCT03147287 | Phase II | Palbociclib Fulvestrant + Palbociclib Avelumab + Fulvestrant + Palbociclib Fulvestrant | Palbociclib After CDK and Endocrine Therapy (PACE) | Active, not recruiting | USA | 0 |
NCT03150576 | Phase II | Carboplatin + Paclitaxel Carboplatin + Olaparib + Paclitaxel | Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer (PARTNER) | Recruiting | GBR | 0 |
NCT03155997 | Phase III | Abemaciclib | Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NZL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 14 |
NCT03166085 | Phase I | Nab-paclitaxel + PU-H71 | PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer | Completed | USA | 0 |
NCT03219476 | Phase II | Anastrozole Letrozole Tamoxifen Exemestane | Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03225547 | Phase II | Mifepristone + Pembrolizumab | Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03241810 | Phase II | Fulvestrant Fulvestrant + Seribantumab | Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC) | Terminated | USA | ESP | DEU | CAN | BEL | AUT | 0 |
NCT03250676 | Phase Ib/II | H3B-6545 | Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer | Completed | USA | GBR | FRA | 0 |
NCT03280563 | Phase Ib/II | Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab + Exemestane Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab + Fulvestrant Atezolizumab + Bevacizumab + Tamoxifen Atezolizumab + Fulvestrant + Ipatasertib Fulvestrant Atezolizumab + Fulvestrant | A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (MORPHEUS HR+BC) | Completed | USA | ISR | 1 |
NCT03284723 | Phase I | Letrozole + Palbociclib + PF-06804103 PF-06804103 | PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors | Terminated | USA | ITA | ESP | AUS | 2 |
NCT03285607 | Phase I | Cyclophosphamide + Doxorubicin + MCS110 + Paclitaxel | MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer | Withdrawn | 0 | |
NCT03286842 | Phase III | Olaparib | To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients. | Completed | USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BGR | 4 |
NCT03294694 | Phase I | Fulvestrant + Ribociclib + Spartalizumab Ribociclib + Spartalizumab | Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer | Terminated | USA | 0 |
NCT03306472 | Phase II | Letrozole + Megestrol acetate Letrozole | A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer (PIONEER) | Completed | GBR | 0 |
NCT03322215 | Phase II | Capecitabine Fulvestrant + Palbociclib | HR+/HER2- Advanced Breast Cancer and Endocrine Resistance (PASIPHAE) | Terminated | SWE | GBR | 0 |
NCT03326674 | Phase III | Capecitabine Capecitabine + Tesetaxel | Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC (CONTESSA) | Terminated | USA | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BEL | AUT | AUS | 6 |
NCT03329937 | Phase I | Niraparib | Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment | Completed | USA | 0 |
NCT03332797 | Phase I | Giredestrant + Palbociclib Giredestrant | A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer | Active, not recruiting | USA | GBR | ESP | AUS | 1 |
NCT03337724 | Phase II | Ipatasertib + Paclitaxel Paclitaxel | A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130) | Completed | USA | TUR | SVN | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 13 |
NCT03344536 | Phase Ib/II | Fulvestrant + Zoligratinib | A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer | Completed | USA | 0 |
NCT03355157 | FDA approved | Exemestane + Palbociclib Tamoxifen Paclitaxel Exemestane Capecitabine Palbociclib + Tamoxifen Epirubicin Vinorelbine Fulvestrant + Palbociclib Fulvestrant Letrozole Letrozole + Palbociclib | A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (PADMA) | Completed | DEU | 0 |
NCT03356860 | Phase Ib/II | Cyclophosphamide + Durvalumab + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel | Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer. (B-IMMUNE) | Completed | BEL | 0 |
NCT03363893 | Phase Ib/II | Samuraciclib Fulvestrant + Samuraciclib | Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies | Completed | USA | GBR | 0 |
NCT03366844 | Phase Ib/II | Pembrolizumab | Breast Cancer Study of Preoperative Pembrolizumab + Radiation | Active, not recruiting | USA | 0 |
NCT03393845 | Phase II | Fulvestrant + Pembrolizumab | Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients | Active, not recruiting | USA | 0 |
NCT03412643 | Phase II | Cyclophosphamide + Doxorubicin Paclitaxel + Pertuzumab + Trastuzumab | Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling (FB-12) | Recruiting | USA | 0 |
NCT03430518 | Phase I | Durvalumab + Eribulin | Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | Completed | USA | 0 |
NCT03439735 | Phase II | Palbociclib Fulvestrant + Palbociclib | Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC | Recruiting | USA | 0 |
NCT03455270 | Phase I | G1T48 G1T48 + Palbociclib | G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer | Completed | USA | NLD | BGR | BEL | 3 |
NCT03471663 | Phase I | D-0502 + Palbociclib D-0502 | A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer | Completed | USA | 1 |
NCT03473639 | Phase I | Capecitabine + Entinostat | A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy (Breast49) | Completed | USA | 0 |
NCT03477396 | Phase II | Ribociclib | Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer | Completed | USA | 0 |
NCT03499353 | Phase II | Talazoparib | Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | Terminated | USA | 0 |
NCT03515798 | Phase II | Cyclophosphamide + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel + Pembrolizumab | Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer (PELICAN) | Active, not recruiting | FRA | 0 |
NCT03519178 | Phase II | PF-06873600 | A Study of PF-06873600 in People With Cancer | Active, not recruiting | USA | CAN | BGR | 3 |
NCT03524170 | Phase I | Bintrafusp alfa + Radiotherapy | Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer | Completed | USA | 0 |
NCT03554044 | Phase I | Letrozole + Talimogene laherparepvec Talimogene laherparepvec + Tamoxifen Exemestane + Talimogene laherparepvec Fulvestrant + Talimogene laherparepvec Anastrozole + Talimogene laherparepvec Nab-paclitaxel + Talimogene laherparepvec Carboplatin + Gemcitabine + Talimogene laherparepvec Paclitaxel + Talimogene laherparepvec | Talimogene Laherparepvec With Chemotherapy or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03555877 | Phase II | Anastrozole Fulvestrant Fulvestrant + Ribociclib Letrozole Exemestane + Ribociclib Letrozole + Ribociclib Anastrozole + Ribociclib Exemestane | Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer (AMICA) | Completed | DEU | 0 |
NCT03560531 | Phase I | Palbociclib + ZN-c5 ZN-c5 | A Study of ZN-c5 in Subjects With Breast Cancer | Completed | USA | LTU | HUN | CZE | 5 |
NCT03566485 | Phase Ib/II | Atezolizumab + Idasanutlin Atezolizumab + Cobimetinib | Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer | Terminated | USA | 0 |
NCT03568422 | Phase Ib/II | CFI-402257 + Paclitaxel | CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer | Active, not recruiting | CAN | 0 |
NCT03595059 | Phase I | Docetaxel + Mirzotamab clezutoclax Mirzotamab clezutoclax + Paclitaxel Mirzotamab clezutoclax | A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors | Active, not recruiting | USA | NLD | ISR | ESP | CAN | AUS | 4 |
NCT03609047 | Phase II | Palbociclib Cyclophosphamide + Epirubicin Paclitaxel Cyclophosphamide + Docetaxel Cyclophosphamide + Doxorubicin | Adjuvant Palbociclib in Elderly Patients With Breast Cancer (Appalaches) | Active, not recruiting | POL | ITA | GBR | FRA | ESP | DEU | BEL | 2 |
NCT03616587 | Phase I | Camizestrant Camizestrant + Palbociclib Camizestrant + Everolimus | Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (SERENA-1) | Active, not recruiting | USA | GBR | ESP | 0 |
NCT03620643 | Phase II | Crizotinib Crizotinib + Fulvestrant | Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours (ROLo) | Active, not recruiting | GBR | 0 |
NCT03624543 | Phase II | CFI-400945 | CFI-400945 in Patients With Advanced/Metastatic Breast Cancer | Active, not recruiting | CAN | 0 |
NCT03628066 | Phase II | Goserelin + Letrozole + Palbociclib | Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer | Completed | USA | CAN | 0 |
NCT03633331 | Phase II | Fulvestrant + Letrozole + Palbociclib | Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer | Unknown status | USA | 0 |
NCT03650894 | Phase II | Bicalutamide + Ipilimumab + Nivolumab | Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients | Active, not recruiting | USA | 0 |
NCT03659136 | Phase II | Everolimus + Exemestane + Xentuzumab Everolimus + Exemestane | The XENERA 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread | Completed | USA | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 1 |
NCT03685331 | Phase I | Fulvestrant + Olaparib + Palbociclib | HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT03685591 | Phase I | PF-06952229 Enzalutamide + PF-06952229 Letrozole + Palbociclib + PF-06952229 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03691493 | Phase II | Letrozole + Palbociclib Palbociclib + Tamoxifen Fulvestrant + Palbociclib Anastrozole + Palbociclib Exemestane + Palbociclib | Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis (ASPIRE) | Completed | USA | 0 |
NCT03701334 | Phase III | Ribociclib | A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE) | Active, not recruiting | USA | ROU | POL | ITA | IRL | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 4 |
NCT03725436 | Phase I | ALRN-6924 + Paclitaxel | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors | Active, not recruiting | USA | 0 |
NCT03774472 | Phase Ib/II | Hydroxychloroquine + Letrozole + Palbociclib | Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer | Completed | USA | 0 |
NCT03781063 | Phase II | Lasofoxifene Fulvestrant | Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Active, not recruiting | USA | ISR | CAN | 0 |
NCT03789110 | Phase II | Ipilimumab + Nivolumab | NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT03803761 | Phase Ib/II | Copanlisib + Fulvestrant | A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer | Withdrawn | USA | 0 |
NCT03804944 | Phase II | CDX-301 CDX-301 + Pembrolizumab Pembrolizumab | Converting HR+ Breast Cancer Into an Individualized Vaccine (CBCV) | Recruiting | USA | 0 |
NCT03809988 | Phase II | Fulvestrant Fulvestrant + Palbociclib Letrozole Letrozole + Palbociclib | PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) | Completed | SVN | ITA | GBR | FRA | ESP | DEU | 0 |
NCT03820830 | Phase III | Anastrozole Exemestane Anastrozole + Palbociclib Letrozole Letrozole + Palbociclib Exemestane + Palbociclib | Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR) | Recruiting | ITA | HUN | FRA | ESP | CHE | AUT | 0 |
NCT03822468 | Phase II | Goserelin + Letrozole + Ribociclib Anastrozole + Ribociclib Anastrozole + Goserelin + Ribociclib Letrozole + Ribociclib | Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (AMALEE) | Completed | USA | SWE | LTU | HUN | FRA | FIN | DEU | CZE | CAN | BRA | BGR | BEL | AUT | ARG | 9 |
NCT03840200 | Phase Ib/II | Ipatasertib + Rucaparib | A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. | Completed | USA | ITA | ESP | AUS | 1 |
NCT03854903 | Phase I | Bosutinib + Palbociclib Bosutinib + Fulvestrant + Palbociclib | WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor | Active, not recruiting | USA | 0 |
NCT03858972 | Phase II | Capecitabine + Tesetaxel | Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC (CONTESSA 2) | Terminated | USA | ESP | CAN | AUS | 2 |
NCT03870919 | FDA approved | Palbociclib | Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients (PALATINE) | Active, not recruiting | FRA | 0 |
NCT03875573 | Phase II | Durvalumab Durvalumab + Oleclumab | Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay) | Active, not recruiting | FRA | BEL | 0 |
NCT03901339 | Phase III | Eribulin Gemcitabine Vinorelbine Capecitabine Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer (TROPiCS-02) | Completed | USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 0 |
NCT03906669 | Phase II | Letrozole Tamoxifen | A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer. (WinPro) | Recruiting | AUS | 0 |
NCT03911973 | Phase Ib/II | Gedatolisib + Talazoparib | Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers | Active, not recruiting | USA | 0 |
NCT03917082 | Phase II | Tamoxifen | Limited Adjuvant Endocrine Therapy for Low Risk Breast Cancer (LALEAST) | Active, not recruiting | CAN | 0 |
NCT03939897 | Phase Ib/II | Abemaciclib + Fulvestrant Abemaciclib + Copanlisib + Fulvestrant | Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT03944434 | Phase II | Anastrozole + Ribociclib Letrozole + Ribociclib Leuprolide Goserelin Triptorelin | FACILE: FeAsibility of First-line riboCIclib in oLdEr Patients With Advanced Breast Cancer (FACILE) | Active, not recruiting | ITA | 0 |
NCT03950570 | Phase I | ORIN1001 + Paclitaxel ORIN1001 | ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT03952325 | Phase II | Pembrolizumab + Tesetaxel Nivolumab + Tesetaxel Tesetaxel Atezolizumab + Tesetaxel | Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC (CONTESSA TRIO) | Terminated | USA | 2 |
NCT03955939 | Phase I | LY3295668 + Midazolam LY3295668 | A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body | Completed | USA | BEL | 0 |
NCT03956654 | FDA approved | Letrozole + Ribociclib | A Phase IV Study to Collect Data on the Efficacy and Safety of RIBociclib in Older Women With Breastcancer (RibOB) | Completed | BEL | 0 |
NCT03959891 | Phase I | Fulvestrant + Ipatasertib + Palbociclib Ipatasertib Fulvestrant + Ipatasertib | AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) | Active, not recruiting | USA | 0 |
NCT03988114 | FDA approved | Abemaciclib + Anastrozole Abemaciclib + Letrozole | A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer (proMONARCH) | Withdrawn | USA | ITA | DEU | BRA | BEL | AUT | ARG | 2 |
NCT03990896 | Phase II | Talazoparib | Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial | Recruiting | USA | 0 |
NCT04024436 | Phase II | Fulvestrant + Futibatinib Futibatinib | A Study of TAS-120 in Patients With Metastatic Breast Cancer | Active, not recruiting | USA | ITA | GBR | FRA | ESP | CAN | 1 |
NCT04031885 | FDA approved | Abemaciclib + Fulvestrant | A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer | Terminated | USA | 1 |
NCT04038489 | Phase II | Aspirin + Cyclophosphamide + Doxorubicin + Paclitaxel + Tamoxifen | COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast Cancer (Breast 51) | Withdrawn | USA | 0 |
NCT04042480 | Phase I | SGN-CD228A | A Study of SGN-CD228A in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | 0 |
NCT04052555 | Phase I | Berzosertib | Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT04053322 | Phase II | Durvalumab + Fulvestrant + Olaparib | Durvalumab, With Olaparib and Fulvestrant in Advanced ER+, HER2- Breast Cancer Patients. (DOLAF) | Active, not recruiting | FRA | 0 |
NCT04055493 | Phase III | Ribociclib | Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC (ADAPTcycle) | Active, not recruiting | DEU | 0 |
NCT04059484 | Phase II | Amcenestrant | Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3) | Active, not recruiting | USA | TUR | POL | LVA | ITA | ISR | GRC | FRA | ESP | CZE | CAN | BRA | BEL | AUS | ARG | 8 |
NCT04060862 | Phase III | Fulvestrant + Ipatasertib + Palbociclib Fulvestrant + Palbociclib | A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer (IPATunity150) | Terminated | USA | GBR | ESP | CAN | BRA | AUS | 2 |
NCT04072952 | Phase Ib/II | Palbociclib + Vepdegestrant Vepdegestrant | A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (mBC) | Active, not recruiting | USA | 0 |
NCT04075604 | Phase II | Anastrozole + Palbociclib Anastrozole + Nivolumab + Palbociclib | A Study of Neoadjuvant Nivolumab + Abemaciclib or Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer (CheckMate 7A8) | Completed | USA | FRA | ESP | DEU | CAN | BEL | AUS | 1 |
NCT04088032 | Phase I | Abemaciclib + Durvalumab + Exemestane Abemaciclib + Anastrozole + Durvalumab Abemaciclib + Durvalumab + Letrozole | Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer | Withdrawn | USA | 0 |
NCT04090567 | Phase II | Cediranib + Olaparib Ceralasertib + Olaparib | Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer | Recruiting | USA | 0 |
NCT04092673 | Phase Ib/II | Fulvestrant + Zotatifin Zotatifin Sotorasib + Zotatifin Abemaciclib + Fulvestrant + Zotatifin Trastuzumab + Zotatifin | Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies (Zotatifin) | Recruiting | USA | 0 |
NCT04095273 | Phase I | Elimusertib + Pembrolizumab | Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the ATR Inhibitor BAY1895344 in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug | Completed | USA | GBR | ESP | DEU | CHE | 0 |
NCT04102618 | Phase I | Atezolizumab + Pelareorep Atezolizumab + Pelareorep + Trastuzumab Letrozole + Pelareorep Atezolizumab + Letrozole + Pelareorep | A Window-of-opportunity Study of Pelareorep in Early Breast Cancer (AWARE-1) | Terminated | ESP | 0 |
NCT04113863 | Phase II | Anastrozole Anastrozole + Tretinoin | Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer (ATRA) | Recruiting | ITA | 0 |
NCT04130152 | Phase I | Letrozole + Palbociclib | Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy | Completed | ESP | 0 |
NCT04132817 | Phase I | Nab-paclitaxel + Nivolumab Ipilimumab + Nab-paclitaxel + Nivolumab | A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread | Completed | USA | 0 |
NCT04134598 | Phase III | Tamoxifen Letrozole Anastrozole Exemestane | ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged >=70 Years Early Stage Breast Cancer (EUROPA) | Recruiting | ITA | 0 |
NCT04142060 | Phase II | Enzalutamide | Targeting PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic Breast Cancer (ARIANNA) | Terminated | ESP | 0 |
NCT04142892 | Phase I | Onapristone | Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer (ONAWA) | Completed | ESP | 0 |
NCT04158362 | Phase III | Capecitabine Abemaciclib + Fulvestrant Abemaciclib + Letrozole Paclitaxel Abemaciclib + Anastrozole | Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (AMBRE) | Active, not recruiting | FRA | 0 |
NCT04174352 | Phase I | Tamoxifen | FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT04176848 | Phase II | CFI-400945 + Durvalumab | CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer | Active, not recruiting | CAN | 0 |
NCT04182516 | Phase I | NMS-03305293 | Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors | Terminated | USA | ITA | GBR | BGR | 1 |
NCT04185311 | Phase I | Ipilimumab + Nivolumab + Talimogene laherparepvec | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted | Terminated | USA | 0 |
NCT04188548 | Phase I | Abemaciclib + LY3484356 LY3484356 Abemaciclib + LY3484356 + Trastuzumab Abemaciclib + Anastrozole + LY3484356 Abemaciclib + Exemestane + LY3484356 Alpelisib + LY3484356 Everolimus + LY3484356 Abemaciclib + Letrozole + LY3484356 | A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER) | Active, not recruiting | USA | FRA | ESP | BEL | AUS | 3 |
NCT04191382 | Phase II | Letrozole Amcenestrant | Phase 2 Window Study of SAR439859 Versus Letrozole in ER+, HER2- Pre-operative Post-menopausal Primary Breast Cancer (AMEERA-4) | Terminated | USA | ITA | FRA | ESP | BEL | 4 |
NCT04191499 | Phase II | Fulvestrant + Palbociclib Fulvestrant + Inavolisib + Palbociclib | A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer (INAVO120) | Active, not recruiting | USA | TUR | POL | NZL | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUS | ARG | 11 |
NCT04214288 | Phase II | Camizestrant Fulvestrant | A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer (SERENA-2) | Active, not recruiting | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | 5 |
NCT04215146 | Phase II | Paclitaxel Avelumab + Paclitaxel + Pelareorep Paclitaxel + Pelareorep | A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | Active, not recruiting | USA | 0 |
NCT04220476 | Phase II | Letrozole + Palbociclib | CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer (CIMER) | Withdrawn | 0 | |
NCT04225117 | Phase II | Enfortumab vedotin-ejfv | A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) | Active, not recruiting | USA | CAN | 1 |
NCT04227327 | Phase II | Abemaciclib + Letrozole Abemaciclib + Anastrozole | Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) (HERMIONE-7) | Active, not recruiting | ITA | 0 |
NCT04240106 | Phase II | Niraparib | Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) | Completed | ESP | 0 |
NCT04243616 | Phase II | Carboplatin + Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel Cemiplimab + Cyclophosphamide + Doxorubicin + Paclitaxel | Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer | Recruiting | USA | 0 |
NCT04251169 | Phase II | Paclitaxel + Pembrolizumab | Pembrolizumab + Paclitaxel in Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-negative (HER2-) Non-luminal (by PAM50) Advanced Breast Cancer After Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitors Progression (TATEN) | Terminated | ESP | 0 |
NCT04274933 | Phase I | Capecitabine + Venetoclax | A Study to Evaluate the Safety and Tolerability of Venetoclax Tablets in Combination With Capecitabine Tablets in Adult Participants With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Had Disease Progression During or After CDK4/6 Inhibitor Therapy | Terminated | USA | DEU | 2 |
NCT04288089 | Phase I | H3B-6545 + Palbociclib | A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer | Active, not recruiting | USA | GBR | 0 |
NCT04293393 | Phase II | Cyclophosphamide + Docetaxel + Doxorubicin Abemaciclib + Letrozole Abemaciclib + Goserelin + Letrozole Abemaciclib + Letrozole + Leuprolide Cyclophosphamide + Doxorubicin + Paclitaxel | Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (CARABELA) | Active, not recruiting | ESP | 0 |
NCT04300790 | Phase II | Alpelisib + Fulvestrant + Metformin | Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients (METALLICA) | Active, not recruiting | ESP | 0 |
NCT04305236 | Phase II | Abemaciclib + Fulvestrant | Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer | Terminated | USA | 0 |
NCT04305496 | Phase III | Capivasertib + Fulvestrant Fulvestrant | Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer (CAPItello-291) | Active, not recruiting | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | ARG | 6 |
NCT04305834 | Phase II | Abemaciclib | Abemaciclib Monotherapy in Treating Older Patients With Hormone Receptor Positive Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT04316169 | Phase I | Abemaciclib + Anastrozole + Hydroxychloroquine Abemaciclib + Fulvestrant + Hydroxychloroquine Abemaciclib + Hydroxychloroquine Abemaciclib + Hydroxychloroquine + Letrozole | Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer | Withdrawn | USA | 0 |
NCT04318223 | Phase II | Palbociclib | Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy | Unknown status | ITA | 0 |
NCT04333706 | Phase Ib/II | Capecitabine Capecitabine + Sarilumab | A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER) | Recruiting | USA | 0 |
NCT04352777 | Phase II | Abemaciclib + Letrozole Abemaciclib + Anastrozole Abemaciclib + Fulvestrant | Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer | Active, not recruiting | USA | 0 |
NCT04432454 | Phase II | Abemaciclib + Lasofoxifene | Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEII) | Active, not recruiting | USA | 0 |
NCT04436744 | Phase II | Giredestrant + Palbociclib Anastrozole + Palbociclib | A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of GDC-9545 Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer | Completed | USA | POL | HUN | ESP | DEU | BRA | AUS | 4 |
NCT04443348 | Phase II | Pembrolizumab Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel + Pembrolizumab | Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) | Recruiting | USA | 0 |
NCT04448886 | Phase II | Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy | Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC | Active, not recruiting | USA | 0 |
NCT04460430 | Phase II | Fulvestrant + Neratinib Neratinib + Tamoxifen Exemestane + Neratinib | Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer (NEREA) | Terminated | ESP | 1 |
NCT04478266 | Phase III | Letrozole + Palbociclib Amcenestrant + Goserelin + Palbociclib Goserelin + Letrozole + Palbociclib Amcenestrant + Palbociclib | SAR439859 Plus Palbociclib as First Line Therapy for Patients With ER(+) HER2(-) Advanced Breast Cancer (AMEERA-5) | Terminated | USA | TUR | POL | NLD | ITA | HUN | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 11 |
NCT04481113 | Phase I | Abemaciclib + Niraparib | Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT04483505 | Phase I | Fulvestrant + Palbociclib + Rogaratinib | Rogaratinib, Palbociclib y Fulvestrant in Patients With Breast Cancer. (ROGABREAST) | Completed | ESP | 0 |
NCT04489173 | Phase II | Trifluridine-tipiracil hydrochloride | TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer (TIBET) | Active, not recruiting | NLD | 0 |
NCT04494425 | Phase III | Capecitabine Nab-paclitaxel Trastuzumab deruxtecan Paclitaxel | Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06) | Active, not recruiting | USA | SWE | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 10 |
NCT04498520 | Phase I | Abexinostat + Fulvestrant + Palbociclib | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | Withdrawn | 0 | |
NCT04504331 | Phase I | Fulvestrant + Infigratinib + Palbociclib Infigratinib + Tamoxifen | Study of Infigratinib in Combination With Tamoxifen or With Fulvestrant and Palbociclib in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer | Terminated | USA | 0 |
NCT04505826 | Phase Ib/II | Palazestrant | A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer | Active, not recruiting | USA | AUS | 0 |
NCT04514159 | Phase I | Abemaciclib + ZN-c5 | A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer | Completed | USA | POL | 0 |
NCT04546009 | Phase III | Letrozole + Palbociclib Giredestrant + Palbociclib | A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) | Active, not recruiting | USA | TUR | POL | NZL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
NCT04553133 | Phase II | PF-07104091 Letrozole + Palbociclib + PF-07104091 Palbociclib + PF-07104091 | PF-07104091 as a Single Agent and in Combination Therapy | Active, not recruiting | USA | BGR | ARG | 3 |
NCT04556773 | Phase I | Fulvestrant + Trastuzumab deruxtecan Durvalumab + Paclitaxel + Trastuzumab deruxtecan Capivasertib + Trastuzumab deruxtecan Capecitabine + Trastuzumab deruxtecan Anastrozole + Trastuzumab deruxtecan | A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (DB-08) | Active, not recruiting | USA | FRA | CAN | BRA | BEL | AUS | 4 |
NCT04563507 | Phase II | Letrozole + Palbociclib | Combined Immunotherapies in Metastatic ER+ Breast Cancer | Recruiting | USA | 0 |
NCT04565054 | Phase III | Abemaciclib Tamoxifen | Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC (ADAPTlate) | Recruiting | DEU | 0 |
NCT04567420 | Phase II | Fulvestrant + Palbociclib | DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer (DARE) | Recruiting | USA | 0 |
NCT04568616 | Phase II | Letrozole | Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) (NAOMI) | Recruiting | USA | 0 |
NCT04576455 | Phase II | Fulvestrant Giredestrant | A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) | Active, not recruiting | USA | TUR | POL | ISR | GBR | DEU | BRA | AUS | ARG | 8 |
NCT04579380 | Phase II | Trastuzumab + Tucatinib Fulvestrant + Trastuzumab + Tucatinib | Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations | Active, not recruiting | USA | POL | NLD | ITA | GBR | ESP | DEU | BEL | 2 |
NCT04584255 | Phase II | Dostarlimab-gxly + Niraparib Niraparib | Niraparib + Dostarlimab In BRCA Mutated Breast Cancer | Recruiting | USA | 0 |
NCT04584853 | Phase III | Abemaciclib | PreOperative Endocrine Therapy for Individualised Care With Abemaciclib (POETIC-A) | Recruiting | GBR | 0 |
NCT04585724 | Phase I | Abemaciclib Palbociclib Ribociclib | Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases | Withdrawn | 0 | |
NCT04586270 | Phase I | TAS0612 | A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer | Recruiting | USA | FRA | 0 |
NCT04588298 | Phase II | Camizestrant | A Study to Investigate the Biological Effects of AZD9833 in Women With ER-positive, HER2 Negative Primary Breast Cancer (SERENA-3) | Completed | GBR | 2 |
NCT04595565 | Phase III | Sacituzumab govitecan-hziy Cisplatin Carboplatin Capecitabine | Sacituzumab Govitecan in Primary HER2-negative Breast Cancer (SASCIA) | Active, not recruiting | IRL | FRA | ESP | DEU | CHE | BEL | AUT | 0 |
NCT04596150 | Phase II | CX-2009 CX-072 + CX-2009 | Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer | Completed | USA | ESP | 1 |
NCT04603183 | Phase II | Abemaciclib + Fulvestrant + Letrozole Paclitaxel | ABemaciclib, ET +/- paclItaxel in aGgressive HR+/HER2- MBC trIaL (ABIGAIL) | Active, not recruiting | ITA | ESP | 1 |
NCT04606446 | Phase I | PF-07248144 Fulvestrant + Palbociclib + PF-07248144 Fulvestrant + PF-07248144 Letrozole + Palbociclib + PF-07248144 | Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6) | Recruiting | USA | AUS | 3 |
NCT04610528 | Phase I | Patritumab deruxtecan | A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression (TOT-HER3) | Active, not recruiting | ESP | 0 |
NCT04614194 | Phase II | Letrozole Abemaciclib + Letrozole | Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib | Recruiting | USA | 0 |
NCT04616248 | Phase I | CDX-1140 + CDX-301 + Poly ICLC | In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT04647487 | Phase I | LY3484356 | A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (EMBER-2) | Completed | USA | GBR | FRA | ESP | DEU | BEL | 0 |
NCT04647916 | Phase II | Sacituzumab govitecan-hziy | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases | Recruiting | USA | 0 |
NCT04650581 | Phase III | Fulvestrant Fulvestrant + Ipatasertib | Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER) | Active, not recruiting | NZL | CAN | AUS | 0 |
NCT04655183 | Phase Ib/II | Niraparib + VX-803 Niraparib | Study of M4344 in Combination With Niraparib | Withdrawn | 0 | |
NCT04657679 | Phase 0 | Fulvestrant + Ribociclib Letrozole + Ribociclib | Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts (LEANORA) | Terminated | USA | 0 |
NCT04665921 | Phase I | SGN-STNV | A Study of SGN-STNV in Advanced Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | CAN | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04691375 | Phase I | Pembrolizumab + PY314 PY314 | A Study of PY314 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04703920 | Phase I | Belinostat + Talazoparib | Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | Active, not recruiting | USA | 0 |
NCT04711252 | Phase III | Anastrozole + Palbociclib Camizestrant + Palbociclib | A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4) | Active, not recruiting | USA | TUR | SVK | POL | NOR | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BGR | BEL | AUT | 10 |
NCT04711824 | Phase Ib/II | Nab-paclitaxel Carboplatin + Gemcitabine Cisplatin Durvalumab + Olaparib Paclitaxel Capecitabine Gemcitabine Carboplatin Eribulin | Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases (SOLARA) | Recruiting | USA | 0 |
NCT04714619 | Phase II | Anastrozole + CB-103 CB-103 + Letrozole | CB-103 Plus NSAI In Luminal Advanced Breast Cancer (CAILA) | Terminated | ESP | 0 |
NCT04720664 | Phase II | Methoxsalen + Phenytoin + Sirolimus + SM88 | Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer (OASIS) | Terminated | USA | 0 |
NCT04726332 | Phase I | Abiraterone + Prednisone + XL102 Fulvestrant + XL102 XL102 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) | Terminated | USA | 0 |
NCT04738292 | Phase II | Fulvestrant + Onapristone | Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) | Terminated | USA | 0 |
NCT04756505 | Phase I | Bintrafusp alfa + NHS-IL12 | Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial | Withdrawn | 0 | |
NCT04756765 | Phase II | Talazoparib | Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer | Recruiting | USA | 0 |
NCT04762979 | Phase II | Alpelisib + Fulvestrant | Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT04791384 | Phase Ib/II | Abemaciclib + Elacestrant | Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer | Recruiting | USA | 0 |
NCT04797728 | Phase I | Elacestrant | Elacestrant in Preoperative Setting, a Window of Opportunity Study (ELIPSE) | Completed | ESP | 0 |
NCT04841148 | Phase II | Hydroxychloroquine Avelumab + Palbociclib Hydroxychloroquine + Palbociclib Avelumab | Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer (PALAVY) | Recruiting | USA | 0 |
NCT04851613 | Phase I | Afuresertib + Fulvestrant | Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer | Recruiting | USA | 1 |
NCT04862663 | Phase III | Capivasertib + Fulvestrant + Ribociclib Abemaciclib + Capivasertib + Fulvestrant Capivasertib + Fulvestrant + Palbociclib Fulvestrant + Palbociclib | Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (CAPItello-292) | Recruiting | USA | TUR | SWE | POL | ITA | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUS | ARG | 8 |
NCT04869943 | Phase III | Exemestane Enobosarm | Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer (ARTEST) | Terminated | USA | POL | ESP | 1 |
NCT04872166 | Phase I | BTX-A51 | A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer | Recruiting | USA | 0 |
NCT04872608 | Phase I | Letrozole + Onapristone + Palbociclib | A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer | Withdrawn | USA | 0 |
NCT04895358 | Phase III | Nab-paclitaxel Nab-paclitaxel + Pembrolizumab Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab Capecitabine Pegylated liposomal doxorubicin Paclitaxel Pegylated liposomal doxorubicin + Pembrolizumab | Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) | Active, not recruiting | USA | TUR | SWE | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG | 11 |
NCT04895761 | Phase I | Letrozole + Maveropepimut-S Cyclophosphamide + Letrozole + Maveropepimut-S | Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer | Active, not recruiting | USA | 0 |
NCT04901299 | Phase II | Fulvestrant + Neratinib | Fulvestrant + Neratinib In Breast Cancer (HER2-Signal) | Withdrawn | USA | 0 |
NCT04906395 | Phase III | Anastrozole + Leuprolide + Tamoxifen Exemestane + Leuprolide + Tamoxifen Letrozole + Leuprolide + Tamoxifen | Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (OVELIA) | Recruiting | USA | CAN | BRA | ARG | 3 |
NCT04915755 | Phase III | Niraparib | Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease (ZEST) | Active, not recruiting | USA | ROU | POL | NOR | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 6 |
NCT04920708 | Phase II | Fulvestrant + Ribociclib Fulvestrant + Ipatasertib + Palbociclib Fulvestrant + Palbociclib Abemaciclib + Fulvestrant | Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression (FAIM) | Recruiting | GBR | 0 |
NCT04923542 | Phase Ib/II | Abemaciclib | Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases | Recruiting | USA | 0 |
NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS | 1 |
NCT04946864 | Phase Ib/II | APG-2575 + Palbociclib APG-2575 | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer | Suspended | USA | 1 |
NCT04961996 | Phase III | Exemestane Giredestrant Letrozole Anastrozole | A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | Recruiting | USA | TUR | SWE | SVN | SVK | ROU | POL | NLD | LVA | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 25 |
NCT04964934 | Phase III | Abemaciclib + Camizestrant Letrozole + Palbociclib Abemaciclib + Letrozole Anastrozole + Palbociclib Abemaciclib + Anastrozole Camizestrant + Palbociclib | Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6) | Active, not recruiting | USA | TUR | SVK | POL | NOR | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BGR | BEL | AUT | AUS | 5 |
NCT04965766 | Phase II | Patritumab deruxtecan | Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer (ICARUS-BREAST) | Active, not recruiting | FRA | 0 |
NCT04975308 | Phase III | Exemestane Abemaciclib + LY3484356 LY3484356 Fulvestrant | A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3) | Active, not recruiting | USA | TUR | NLD | ITA | GRC | FRA | ESP | DEU | CZE | BRA | BEL | AUT | AUS | ARG | 8 |
NCT04985266 | Phase II | Exemestane + Tamoxifen Fulvestrant + Palbociclib Anastrozole + Tamoxifen Letrozole + Tamoxifen | A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (TRAK-ER) | Recruiting | GBR | FRA | 0 |
NCT04991480 | Phase Ib/II | ART4215 + Talazoparib ART4215 | A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | GBR | 0 |
NCT05029999 | Phase I | CDX-1140 + CDX-301 + Pegylated liposomal doxorubicin | CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer | Recruiting | USA | 0 |
NCT05033756 | Phase II | Olaparib + Pembrolizumab | Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO (COMPRENDO) | Active, not recruiting | DEU | 0 |
NCT05038735 | Phase III | Alpelisib + Fulvestrant Fulvestrant | Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. (EPIK-B5) | Recruiting | SVK | ROU | POL | ITA | IRL | HUN | GRC | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BGR | BEL | 1 |
NCT05064085 | Phase I | Capecitabine + Cemiplimab | Capecitabine In Combination With Cemiplimab In Patient With Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT05065411 | Phase III | Fulvestrant Exemestane Abemaciclib + Enobosarm Everolimus + Exemestane | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer (VERU-024) | Terminated | USA | 0 |
NCT05067972 | Phase I | PF-07260437 | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (C4431001) | Terminated | USA | 1 |
NCT05069038 | Phase II | Palbociclib | Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy | Recruiting | USA | 0 |
NCT05079360 | Phase II | Everolimus + Exemestane Exemestane VERU-111 | Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer | Withdrawn | USA | 0 |
NCT05080842 | Phase I | AC682 | A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer | Terminated | USA | 0 |
NCT05085002 | Phase II | G1T38 + Letrozole Fulvestrant + G1T38 | A Study of Lerociclib in Participants With Advanced Breast Cancer | Terminated | USA | ITA | BEL | 3 |
NCT05090358 | Phase II | Alpelisib + Fulvestrant Alpelisib + Canagliflozin + Fulvestrant | Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer | Active, not recruiting | USA | 0 |
NCT05095207 | Phase Ib/II | Abemaciclib + Bicalutamide | Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT05098210 | Phase I | NeoVax + Nivolumab + Poly ICLC | Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer | Recruiting | USA | 0 |
NCT05101564 | Phase II | Amcenestrant Alpelisib Infigratinib Tamoxifen Letrozole Amcenestrant + Letrozole | Umbrella Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer | Active, not recruiting | USA | 0 |
NCT05104866 | Phase III | Gemcitabine Capecitabine Datopotamab deruxtecan Vinorelbine Eribulin | A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) | Active, not recruiting | USA | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | ARG | 7 |
NCT05134922 | Expanded access | Gedatolisib | Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009 | Available | USA | 0 |
NCT05143229 | Phase I | Alpelisib + Sacituzumab govitecan-hziy | Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer (ASSET) | Recruiting | USA | 0 |
NCT05159518 | Phase I | PRT2527 | A Study of PRT2527 in Participants With Advanced Solid Tumors | Completed | USA | 0 |
NCT05159778 | Phase II | Pembrolizumab + PGG beta-glucan | Phase 2 Study of Imprime PGG and Pembrolizumab in Patients With HR+/HER2- Metastatic Breast Cancer (mBCA) | Completed | USA | 0 |
NCT05169567 | Phase III | Fulvestrant Abemaciclib + Fulvestrant | Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMONARCH) | Active, not recruiting | USA | TUR | SWE | POL | ITA | ISR | HUN | GRC | FRA | ESP | DNK | CZE | BEL | ARG | 3 |
NCT05183828 | FDA approved | Letrozole | Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer | Recruiting | USA | 0 |
NCT05187832 | Phase I | AND019 | A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT05191004 | Phase Ib/II | NUV-422 Fulvestrant + NUV-422 Fulvestrant | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | Withdrawn | USA | 0 |
NCT05194072 | Phase I | SGN-B7H4V | A Study of SGN-B7H4V in Advanced Solid Tumors | Recruiting | USA | ITA | GBR | ESP | DEU | CAN | 0 |
NCT05203445 | Phase II | Olaparib + Pembrolizumab | A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer | Recruiting | USA | 0 |
NCT05207709 | Phase III | Letrozole + Ribociclib Fulvestrant + Palbociclib Letrozole + Palbociclib Fulvestrant + Ribociclib Paclitaxel | Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype (HARMONIA) | Recruiting | USA | ESP | 1 |
NCT05216432 | Phase I | RLY-2608 Fulvestrant + RLY-2608 | First-in-Human Study of Mutant-selective PI3Kalpha Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer | Recruiting | USA | ITA | FRA | ESP | AUS | 0 |
NCT05243641 | Phase Ib/II | Capmatinib + Neratinib | Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER2 and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test | Recruiting | USA | 0 |
NCT05251714 | Phase Ib/II | CFI-402257 CFI-402257 + Fulvestrant | CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | Recruiting | USA | 0 |
NCT05252416 | Phase Ib/II | BLU-222 + Carboplatin BLU-222 + Fulvestrant + Ribociclib BLU-222 + Fulvestrant | (VELA) Study of BLU-222 in Advanced Solid Tumors | Recruiting | USA | ITA | GBR | 0 |
NCT05261269 | Phase I | DAN-222 DAN-222 + Niraparib | A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer | Completed | USA | 0 |
NCT05262400 | Phase II | Letrozole + PF-07104091 + PF-07220060 Fulvestrant + PF-07104091 + PF-07220060 PF-07104091 + PF-07220060 | A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors | Active, not recruiting | USA | ESP | CZE | BRA | BGR | ARG | 3 |
NCT05296746 | Phase II | Ribociclib | Neoadjuvant and Adjuvant Ribociclib and ET for Clinically High-risk ER+ and HER2- Breast Cancer (RIBOLARIS) | Recruiting | FRA | ESP | 1 |
NCT05304962 | Phase I | RGT-419B | FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT05305924 | Phase II | Fulvestrant Abemaciclib + Fulvestrant | Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT05306340 | Phase III | Everolimus + Fulvestrant Everolimus + Tamoxifen Everolimus + Exemestane Everolimus + Giredestrant | A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) | Active, not recruiting | USA | TUR | ITA | GRC | GBR | ESP | DEU | ARG | 5 |
NCT05307705 | Phase I | Abemaciclib + Anastrozole + LOXO-783 Abemaciclib + Exemestane + LOXO-783 Abemaciclib + Letrozole + LOXO-783 LOXO-783 + Paclitaxel Fulvestrant + LOXO-783 LOXO-783 + LY3484356 Abemaciclib + Fulvestrant + LOXO-783 Abemaciclib + LOXO-783 + LY3484356 Letrozole + LOXO-783 LOXO-783 Anastrozole + LOXO-783 Exemestane + LOXO-783 | A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PIKASSO-01) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS | 4 |
NCT05340413 | Phase II | Olaparib | Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer. (RADIOLA) | Recruiting | ESP | 0 |
NCT05362760 | FDA approved | Abemaciclib + Exemestane Abemaciclib + Fulvestrant Abemaciclib + Letrozole Abemaciclib + Anastrozole | Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management (MINERVA) | Recruiting | DEU | CHE | 0 |
NCT05384119 | Phase Ib/II | C188-9 + Palbociclib C188-9 + Fulvestrant C188-9 + Ribociclib Fulvestrant | Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer | Completed | USA | 0 |
NCT05386108 | Phase Ib/II | Abemaciclib + Elacestrant | Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer (ELECTRA) | Recruiting | USA | TUR | ITA | GRC | GBR | FRA | ESP | DEU | BEL | 1 |
NCT05392608 | Phase II | Alpelisib + Fulvestrant | SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast) (SEQUEL-Breast) | Recruiting | NLD | 0 |
NCT05394103 | Phase Ib/II | Q901 | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05417594 | Phase Ib/II | AZD9574 AZD9574 + Temozolomide | Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) | Recruiting | USA | SWE | GBR | ESP | DEU | AUS | 1 |
NCT05438329 | Phase Ib/II | DB-1305 | First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT05447910 | Phase II | Letrozole | Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer | Completed | USA | 0 |
NCT05452213 | FDA approved | Ribociclib | Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients (CAPTOR-BC) | Recruiting | DEU | 0 |
NCT05455619 | Phase Ib/II | Capivasertib + Fulvestrant + SDX-7320 Alpelisib + Fulvestrant + SDX-7320 | Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Women With a PI3K Alteration and HR+/Her2- Breast Cancer (Amelia-1) | Recruiting | USA | 0 |
NCT05464810 | Phase I | Letrozole + Simvastatin Letrozole | Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer | Recruiting | USA | 0 |
NCT05467891 | Phase II | Fulvestrant + Ribociclib Anastrozole + Ribociclib Letrozole + Ribociclib Exemestane + Ribociclib | Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR) | Recruiting | USA | 0 |
NCT05472792 | Phase II | Toremifene Exemestane Tamoxifen Letrozole Anastrozole Fulvestrant | Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN) (CAMERAN) | Recruiting | USA | 0 |
NCT05498155 | Phase II | Olaparib Durvalumab + Olaparib | Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer (OlympiaN) | Active, not recruiting | USA | ITA | ISR | GBR | ESP | DEU | BEL | AUT | AUS | 0 |
NCT05501704 | Phase II | Tamoxifen Abemaciclib + Tamoxifen Abemaciclib + Anastrozole + Degarelix Anastrozole + Degarelix Anastrozole | ETHAN - ET for Male BC | Recruiting | USA | 0 |
NCT05501769 | Phase I | Everolimus + Vepdegestrant | ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer (TACTIVE-E) | Active, not recruiting | USA | ESP | 0 |
NCT05501886 | Phase III | Alpelisib + Fulvestrant Fulvestrant + Gedatolisib + Palbociclib Fulvestrant + Gedatolisib Fulvestrant | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (VIKTORIA-1) | Recruiting | USA | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 5 |
NCT05504707 | Phase I | HER2-pulsed DC1 vaccine HER3-primed DC1 vaccine | DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER) | Recruiting | USA | 0 |
NCT05508906 | Phase I | Alpelisib + Palazestrant Palazestrant + Ribociclib | Phase 1b Combo w/ Ribociclib and Alpelisib | Recruiting | USA | AUS | 0 |
NCT05512364 | Phase III | Letrozole Anastrozole Exemestane Elacestrant Tamoxifen | Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) (TREAT ctDNA) | Recruiting | ITA | IRL | FRA | DEU | BEL | 0 |
NCT05514054 | Phase III | Letrozole Anastrozole Exemestane Tamoxifen LY3484356 | A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4) | Recruiting | USA | TUR | SVK | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT05524584 | Phase II | Abemaciclib + Anastrozole + Fulvestrant | Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT05548127 | Phase Ib/II | Abemaciclib + Vepdegestrant | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) | Recruiting | USA | ITA | ESP | CAN | 0 |
NCT05549505 | Phase II | Anastrozole Vepdegestrant | A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery | Completed | USA | ESP | DEU | 1 |
NCT05554354 | Phase II | Binimetinib + Fulvestrant Fulvestrant | Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) | Recruiting | USA | 1 |
NCT05563220 | Phase Ib/II | Alpelisib + Elacestrant Elacestrant + Ribociclib Elacestrant + Everolimus Elacestrant + Palbociclib Abemaciclib + Elacestrant | Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (ELEVATE) | Recruiting | USA | TUR | POL | LUX | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | ARG | 1 |
NCT05564377 | Phase II | Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Recruiting | USA | 1 |
NCT05569811 | Phase II | Letrozole + Patritumab deruxtecan Patritumab deruxtecan | NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial (VALENTINE) | Active, not recruiting | ESP | 0 |
NCT05573126 | Phase Ib/II | RAD140 | Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer | Recruiting | USA | GBR | ESP | 0 |
NCT05573555 | Phase II | Ribociclib + Vepdegestrant | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B) | Recruiting | USA | ITA | ESP | CAN | 0 |
NCT05579366 | Phase Ib/II | PRO1184 | PRO1184 for Advanced Solid Tumors (PRO1184-001) | Recruiting | USA | 1 |
NCT05596409 | Phase II | Elacestrant | ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study (ELCIN) | Recruiting | USA | ROU | BRA | BGR | 1 |
NCT05607004 | Phase II | Goserelin + Z-endoxifen HCl Z-endoxifen HCl Exemestane + Goserelin | (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (EVANGELINE) | Recruiting | USA | 0 |
NCT05608252 | Phase Ib/II | Abemaciclib + Fulvestrant + RO5126766 | VS-6766+Abema+Fulv in Met HR+/HER- BC | Recruiting | USA | 0 |
NCT05618613 | Phase Ib/II | Elacestrant + Onapristone | Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer (ELONA) | Active, not recruiting | USA | 0 |
NCT05620914 | Phase I | Patritumab deruxtecan | A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) | Not yet recruiting | USA | 0 |
NCT05622058 | Phase I | ALRN-6924 + Cyclophosphamide + Docetaxel + Doxorubicin | A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer | Terminated | USA | BGR | 2 |
NCT05625087 | Phase II | Fulvestrant + Ribociclib Alpelisib + Fulvestrant | Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib (SAFIR 03) | Recruiting | FRA | 0 |
NCT05633979 | Phase I | DS-3201b DS-3201b + Trastuzumab deruxtecan | Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT05646862 | Phase III | Alpelisib + Fulvestrant Fulvestrant + Inavolisib | A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy (INAVO121) | Recruiting | USA | TUR | POL | ITA | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG | 6 |
NCT05653752 | Phase I | YL202 | A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer | Recruiting | USA | 1 |
NCT05654532 | Phase I | AC699 | Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT05654623 | Phase III | Fulvestrant Vepdegestrant | A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2) | Recruiting | USA | TUR | SWE | SVK | POL | NOR | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 8 |
NCT05655598 | Phase I | Palbociclib + Pimitespib | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Withdrawn | USA | 0 |
NCT05659563 | Phase II | Tamoxifen Giredestrant | Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67>=10% (EMPRESS) | Recruiting | FRA | ESP | 0 |
NCT05660083 | Phase II | Alpelisib + L-NMMA + Nab-paclitaxel | Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) | Recruiting | USA | 0 |
NCT05664893 | Phase Ib/II | Ribociclib | Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS) (CALHYS) | Recruiting | FRA | 0 |
NCT05675579 | Phase II | Pembrolizumab + Sacituzumab govitecan-hziy | A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) | Recruiting | USA | 0 |
NCT05683418 | Phase I | TOS-358 | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors | Recruiting | USA | 0 |
NCT05708235 | Phase II | Giredestrant + Inavolisib Abemaciclib + Giredestrant Giredestrant | A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population (MiRaDoR) | Active, not recruiting | GBR | ESP | 0 |
NCT05720117 | Phase I | PYX-201 | Study of PYX-201 in Solid Tumors | Recruiting | USA | ESP | BEL | 0 |
NCT05735080 | Phase Ib/II | INX-315 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01) | Recruiting | USA | AUS | 0 |
NCT05747794 | Phase II | Paclitaxel Eftilagimod alpha + Paclitaxel | Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy (AIPAC-003) | Recruiting | USA | ESP | BEL | 2 |
NCT05759949 | Phase I | Fulvestrant + RLY-5836 RLY-5836 Fulvestrant + Palbociclib + RLY-5836 Abemaciclib + Fulvestrant + RLY-5836 Fulvestrant + Ribociclib + RLY-5836 | First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors | Active, not recruiting | USA | 0 |
NCT05768139 | Phase Ib/II | Fulvestrant + STX-478 STX-478 | First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | 0 |
NCT05774951 | Phase III | Tamoxifen Exemestane Anastrozole Letrozole Camizestrant | A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 18 |
NCT05791474 | Phase Ib/II | Capecitabine + Denosumab ATI-2231 + Capecitabine ATI-2231 Bisphosphonate + Capecitabine | ATI-2231 With in Advanced Solid Tumor Malignancies Followed by ATI-2231 in Combination With Capecitabine in Patients With Hormone Receptor-positive and HER2 Negative Metastatic Breast Cancer | Withdrawn | 0 | |
NCT05826964 | Phase II | Everolimus + Fulvestrant Exemestane + Ribociclib Everolimus + Tamoxifen Fulvestrant + Ribociclib Everolimus + Exemestane Abemaciclib + Letrozole Anastrozole + Palbociclib Abemaciclib + Anastrozole Alpelisib + Letrozole Abemaciclib + Exemestane Fulvestrant + Palbociclib Alpelisib + Fulvestrant Letrozole + Palbociclib Exemestane + Palbociclib Anastrozole + Ribociclib Letrozole + Ribociclib Abemaciclib + Fulvestrant | Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer | Recruiting | USA | 0 |
NCT05827081 | Phase III | Exemestane + Leuprolide + Ribociclib Letrozole + Leuprolide + Ribociclib Goserelin + Letrozole + Ribociclib Anastrozole + Ribociclib Anastrozole + Goserelin + Ribociclib Exemestane + Goserelin + Ribociclib Exemestane + Ribociclib Anastrozole + Leuprolide + Ribociclib Letrozole + Ribociclib | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (Adjuvant WIDER) | Suspended | AUS | 0 |
NCT05837455 | Phase II | Anastrozole | NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer | Recruiting | USA | 0 |
NCT05840211 | Phase III | Paclitaxel Capecitabine Nab-paclitaxel Sacituzumab govitecan-hziy | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07) | Active, not recruiting | USA | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 11 |
NCT05867251 | Phase Ib/II | ARTS-021 + Fulvestrant + Ribociclib ARTS-021 + Letrozole + Ribociclib ARTS-021 + Fulvestrant + Palbociclib ARTS-021 + Letrozole + Palbociclib ARTS-021 + Carboplatin Abemaciclib + ARTS-021 + Fulvestrant Abemaciclib + ARTS-021 + Letrozole ARTS-021 + Fulvestrant ARTS-021 | Study of AVZO-021 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05870579 | Phase I | 177Lu-NeoB + Fulvestrant + Ribociclib Goserelin | [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer | Recruiting | POL | FRA | ESP | DEU | 1 |
NCT05896566 | Phase II | Anastrozole + Triptorelin Giredestrant + Triptorelin Giredestrant | A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer (PREcoopERA) | Recruiting | SWE | ITA | IRL | HUN | FRA | ESP | DEU | CHE | 0 |
NCT05898399 | Phase Ib/II | Olaparib ART6043 Talazoparib ART6043 + Olaparib ART6043 + Talazoparib | Study of ART6043 in Advanced/Metastatic Solid Tumors Patients | Recruiting | USA | 0 |
NCT05909397 | Phase III | Letrozole + Palbociclib Palbociclib + Vepdegestrant | A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer (VERITAC-3) | Active, not recruiting | USA | SVK | ITA | HUN | ESP | CHE | BRA | AUS | 2 |
NCT05919108 | Phase II | Neratinib | Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers | Recruiting | USA | 0 |
NCT05932667 | Phase II | Fulvestrant + Milademetan | Milademetan and Fulvestrant in GATA3-mutant, ER+HER- Advanced or Metastatic Breast Cancer (DEMETER) | Terminated | FRA | 0 |
NCT05952557 | Phase III | Tamoxifen Abemaciclib + Tamoxifen Abemaciclib + Exemestane Abemaciclib + Camizestrant Abemaciclib + Letrozole Abemaciclib + Anastrozole Exemestane Anastrozole Letrozole | An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2) | Recruiting | USA | TUR | ROU | POL | NZL | ITA | ISR | IRL | HUN | HRV | GRC | GBR | FRA | EST | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 19 |
NCT05963984 | Phase II | Fulvestrant + Samuraciclib Fulvestrant | A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (SUMIT-BC) | Active, not recruiting | USA | TUR | HUN | ESP | 1 |
NCT05963997 | Phase Ib/II | Elacestrant + Samuraciclib | A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer (SUMIT-ELA) | Active, not recruiting | USA | GBR | FRA | ESP | 0 |
NCT05967884 | Phase II | Cemiplimab Cemiplimab + Dupilumab | PD-1 +/- IL-4 Inhibition in ER+ Breast Cancer | Not yet recruiting | CAN | 0 |
NCT05969041 | Phase I | MT-302 | Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE Symphony) | Recruiting | AUS | 0 |
NCT05985655 | Phase Ib/II | GTAEXS617 | Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (ELUCIDATE) | Recruiting | GBR | BEL | 0 |
NCT05986071 | Phase Ib/II | Fulvestrant + M1774 | I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers (MATRIX) | Not yet recruiting | FRA | 0 |
NCT05996107 | Phase I | Ribociclib | Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer | Suspended | USA | 0 |
NCT06001762 | Phase II | Tamoxifen Exemestane Abemaciclib Anastrozole Letrozole | TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer | Active, not recruiting | USA | 0 |
NCT06014658 | Phase I | MBRC-101 | Safety & PK of MBRC-101 in Advanced Refractory Solid Tumors | Recruiting | USA | 0 |
NCT06016738 | Phase III | Fulvestrant Letrozole Anastrozole Palazestrant Exemestane | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01) | Recruiting | USA | ROU | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG | 8 |
NCT06026657 | Phase Ib/II | Gemcitabine + TGF-beta-imprinted NK cells Gemcitabine + Naxitamab + TGF-beta-imprinted NK cells | Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFbeta-i Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer | Recruiting | USA | 0 |
NCT06044623 | Phase III | Exemestane Abemaciclib Palbociclib Ribociclib Letrozole Anastrozole Fulvestrant | Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients (IMPORTANT) | Recruiting | SWE | NOR | ITA | GRC | FIN | ESP | 0 |
NCT06058377 | Phase III | Cyclophosphamide + Doxorubicin + Durvalumab + Paclitaxel Cyclophosphamide + Doxorubicin + Paclitaxel | Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Recruiting | USA | 1 |
NCT06062498 | Phase II | Abemaciclib + Elacestrant Elacestrant Elacestrant + Palbociclib Elacestrant + Ribociclib | Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer | Not yet recruiting | USA | 0 |
NCT06065748 | Phase III | Fulvestrant + Palbociclib Abemaciclib + Fulvestrant Giredestrant + Ribociclib Giredestrant + Palbociclib Abemaciclib + Giredestrant Fulvestrant + Ribociclib | A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Recruiting | USA | SVN | POL | NZL | ITA | ISR | HUN | GRC | FRA | FIN | ESP | DEU | CAN | BRA | BEL | AUT | AUS | ARG | 15 |
NCT06066424 | Phase I | Cyclophosphamide + Fludarabine TROP2-CAR/IL15-transduced CBNK cells Rimiducid | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | Recruiting | USA | 0 |
NCT06084481 | Phase I | ABBV-400 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 | Recruiting | USA | ISR | ESP | AUS | 4 |
NCT06099769 | Phase II | Capecitabine Paclitaxel Enzalutamide Enzalutamide + Mifepristone Eribulin Carboplatin | A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT06105632 | Phase III | Fulvestrant Everolimus + Exemestane Fulvestrant + PF-07220060 | A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment | Recruiting | USA | TUR | ISR | GBR | CHE | CAN | BRA | AUS | ARG | 7 |
NCT06110793 | Phase Ib/II | Fulvestrant + Lenvatinib + Pembrolizumab | A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer | Recruiting | USA | 0 |
NCT06112379 | Phase III | Carboplatin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel Capecitabine Carboplatin + Cyclophosphamide + Doxorubicin + Paclitaxel Cyclophosphamide + Doxorubicin + Pembrolizumab Cyclophosphamide + Epirubicin + Pembrolizumab Datopotamab deruxtecan + Durvalumab Cyclophosphamide + Doxorubicin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab | A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer | Recruiting | USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | 10 |
NCT06120283 | Phase I | BGB-43395 BGB-43395 + Letrozole BGB-43395 + Fulvestrant | BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | Recruiting | USA | FRA | AUS | 0 |
NCT06125522 | Phase II | Samuraciclib + Vepdegestrant | TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C) | Recruiting | USA | ITA | FRA | ESP | CAN | BEL | 1 |
NCT06139107 | Phase I | Abemaciclib + Letrozole | RADIANT: Pre-op Radiation With Abemaciclib and Letrozole | Recruiting | USA | 0 |
NCT06167317 | Phase I | GS-0201 + Sacituzumab govitecan-hziy GS-0201 | Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors | Recruiting | USA | ISR | 0 |
NCT06169371 | FDA approved | Abemaciclib | Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI) (BRE-09) | Recruiting | USA | 0 |
NCT06176261 | Phase II | Datopotamab deruxtecan | DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | Recruiting | USA | 0 |
NCT06179303 | Phase II | Tamoxifen Exemestane Abemaciclib Fulvestrant Letrozole Anastrozole | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | Suspended | USA | 0 |
NCT06188520 | Phase Ib/II | AZD8421 + Camizestrant + Palbociclib AZD8421 + Camizestrant + Ribociclib Abemaciclib + AZD8421 + Camizestrant AZD8421 | A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors (CYCAD-1) | Recruiting | USA | GBR | ESP | AUS | 1 |
NCT06193525 | Phase II | Talazoparib | FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test (FUTURE) | Recruiting | NLD | 0 |
NCT06201234 | Phase II | Niraparib Elacestrant + Niraparib | Evaluating the Addition of Elacestrant (Oral SERD) to Niraparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer (ELEMENT) | Recruiting | DEU | 0 |
NCT06206837 | Phase I | PF-07220060 + Vepdegestrant | A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer. | Recruiting | USA | FRA | ESP | CAN | BEL | 3 |
NCT06214793 | Phase II | Taletrectinib | Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) | Suspended | USA | 0 |
NCT06223698 | Phase III | Letrozole Anastrozole Exemestane Tamoxifen | Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer (SWE-Switch) | Not yet recruiting | SWE | 0 |
NCT06236269 | Phase II | Sacituzumab govitecan-hziy | HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan (ACROSS-TROP2) | Recruiting | ESP | 0 |
NCT06257264 | Phase I | BG-68501 + Fulvestrant BG-68501 | A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | Recruiting | USA | AUS | 1 |
NCT06259929 | Phase II | Abemaciclib + Giredestrant | NEOadjuvant Abemaciclib and GIredestrant triaL in Patients With ER-positive, HER2-negative Early Breast Cancer (Neo-AGILE) | Not yet recruiting | ITA | 0 |
NCT06264921 | Phase I | NKT3447 | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06312176 | Phase III | Paclitaxel Capecitabine Pegylated liposomal doxorubicin Nab-paclitaxel Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | Recruiting | USA | ROU | POL | NZL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | CHE | CAN | BRA | BEL | AUS | ARG | 12 |
NCT06334432 | Phase Ib/II | NUV-1511 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06374459 | Phase Ib/II | ATI-450 + Capecitabine Capecitabine + Zoledronic acid Capecitabine + Denosumab | Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis | Not yet recruiting | USA | 0 |
NCT06377852 | Phase III | Letrozole + Ribociclib Exemestane + Palbociclib Fulvestrant + Ribociclib Anastrozole + Palbociclib Anastrozole + Ribociclib Exemestane + Ribociclib Letrozole + Palbociclib Fulvestrant + Palbociclib | The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | Recruiting | USA | 0 |
NCT06380751 | Phase III | Ribociclib Fulvestrant Camizestrant + Saruparib Anastrozole Camizestrant + Ribociclib Letrozole Camizestrant + Palbociclib Abemaciclib + Camizestrant Exemestane Abemaciclib Palbociclib | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01) | Recruiting | USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | AUT | AUS | ARG | 11 |
NCT06408168 | Phase II | Repotrectinib Fulvestrant + Repotrectinib | Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial) | Recruiting | USA | 0 |
NCT06409390 | Phase I | Fulvestrant + Ribociclib Trastuzumab deruxtecan Sacituzumab govitecan-hziy Capecitabine Abemaciclib + Fulvestrant Cyclophosphamide + Docetaxel + Sargramostim | Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | Recruiting | USA | 0 |
NCT06428396 | Phase II | Everolimus + Exemestane Everolimus + Fulvestrant Belzutifan + Fulvestrant | Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | Recruiting | USA | 1 |
NCT06465368 | Phase II | Letrozole Letrozole + PF-07220060 | A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause | Recruiting | USA | SWE | SVK | POL | ITA | ESP | BEL | AUS | 2 |
NCT06472583 | Phase II | Pembrolizumab | Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer (BREAST-BOOSTER) | Recruiting | POL | 0 |
NCT06488378 | Phase I | Axatilimab + Olaparib | Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer | Recruiting | USA | 0 |
NCT06492616 | Phase III | Exemestane Elacestrant Tamoxifen Letrozole Anastrozole | A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT) | Recruiting | USA | 0 |
NCT06515470 | Phase I | BTX-9341 BTX-9341 + Fulvestrant | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer | Recruiting | USA | 0 |
NCT06586957 | Phase I | NKT3964 | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT06590857 | Phase Ib/II | Pembrolizumab + RYZ101 RYZ101 | Trial of 225Ac-DOTATATE (RYZ101) Alone and with Pembrolizumab in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs (TRACY-1) | Recruiting | USA | 0 |
NCT06613516 | Phase II | Capivasertib | Effect of Capivasertib on ctDNA in ER Positive Breast Cancer (CaptAin) | Not yet recruiting | GBR | 0 |
NCT06625515 | Phase I | ATX-559 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients with Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers | Recruiting | USA | 0 |
NCT06625775 | Phase I | BBO-10203 + Trastuzumab BBO-10203 | Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101) | Recruiting | USA | 0 |
NCT06678269 | Phase I | Abemaciclib | A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer | Not yet recruiting | USA | 0 |